Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study

[1]  B. Pulendran,et al.  Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination , 2022, Nature immunology.

[2]  A. Haque,et al.  Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population , 2022, Scientific Reports.

[3]  H. Schuitemaker,et al.  Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials , 2022, Vaccine.

[4]  A. Sette,et al.  Humoral and cellular immune memory to four COVID-19 vaccines , 2022, Cell.

[5]  N. Sheils,et al.  Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine , 2022, Nature Communications.

[6]  S. Jeon,et al.  Demographic and Clinical Factors Associated With Anti–SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses , 2022, JAMA network open.

[7]  R. Sanders,et al.  Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study , 2022, PLoS medicine.

[8]  B. Pulendran,et al.  Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses , 2022, bioRxiv.

[9]  E. Estenssoro,et al.  Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study , 2022, The Lancet Regional Health - Americas.

[10]  Angelia A. Eick-Cost,et al.  Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant , 2022, JAMA network open.

[11]  E. Wherry,et al.  Understanding T cell responses to COVID-19 is essential for informing public health strategies , 2022, Science Immunology.

[12]  M. Mulligan,et al.  Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies , 2022, Frontiers in Immunology.

[13]  K. Miyo,et al.  Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine , 2022, Obesity.

[14]  Paul J. Birrell,et al.  Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines , 2022, Nature Medicine.

[15]  R. Polosa,et al.  The Effect of Smoking on Humoral Response to COVID-19 Vaccines: A Systematic Review of Epidemiological Studies , 2022, Vaccines.

[16]  J. Mascola,et al.  SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination , 2022, The New England journal of medicine.

[17]  H. Leier,et al.  Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants , 2022, Science Immunology.

[18]  N. Volkow,et al.  Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. , 2022, JAMA.

[19]  D. Freilich,et al.  Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers , 2022, International Journal of Infectious Diseases.

[20]  V. Tomaselli,et al.  Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studies , 2022, Public Health.

[21]  M. Reindl,et al.  Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern , 2022, Journal of Allergy and Clinical Immunology.

[22]  D. Douek,et al.  mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant , 2022, Cell Reports Medicine.

[23]  R. Baric,et al.  SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people , 2022, Cell Reports.

[24]  S. Antinori,et al.  Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy , 2021, Human vaccines & immunotherapeutics.

[25]  Jordan J. Clark,et al.  Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron , 2021, Nature.

[26]  Maristela L Onozato,et al.  Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines , 2021, The Journal of infectious diseases.

[27]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[28]  Michael I. Mandel,et al.  Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.

[29]  J. Alcorn,et al.  Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S , 2021, npj Vaccines.

[30]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.

[31]  L. Heylen,et al.  Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.

[32]  K. Sugiyama,et al.  Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine , 2021, medRxiv.

[33]  J. Polesel,et al.  Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis , 2021, Vaccines.

[34]  H. Leier,et al.  Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples. , 2021, JAMA.

[35]  H. Schuitemaker,et al.  Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination , 2021, The New England journal of medicine.

[36]  C. Knabbe,et al.  SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study , 2021, Vaccine.

[37]  B. Mustanski,et al.  COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men , 2021, The Journal of infectious diseases.

[38]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[39]  S. O’Rahilly,et al.  Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study , 2021, The Lancet Diabetes & Endocrinology.

[40]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[41]  D. Freedman,et al.  Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[42]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[43]  D. Weissman,et al.  D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization , 2020, Cell Host & Microbe.

[44]  Paul A. Harris,et al.  The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.

[45]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[46]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[47]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[48]  S. Leeder,et al.  A systematic review of epidemiological studies on the association between smokeless tobacco use and coronary heart disease , 2011 .

[49]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[50]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[51]  Øyvind Langsrud,et al.  ANOVA for unbalanced data: Use Type II instead of Type III sums of squares , 2003, Stat. Comput..

[52]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[53]  I. Symington,et al.  Influence of smoking on immunological responses to hepatitis B vaccine. , 1994, Vaccine.

[54]  V. Hasselblad,et al.  Cigarette smoking and hemagglutination inhibition response to influenza after natural disease and immunization. , 2015, The American review of respiratory disease.